<DOC>
	<DOCNO>NCT00454376</DOCNO>
	<brief_summary>RATIONALE : Questionnaires measure quality life may help doctor identify effect treatment improve ability plan treatment patient gastrointestinal-related neuroendocrine tumor . PURPOSE : This phase IV clinical trial study well disease-specific questionnaire work assess quality life patient gastrointestinal-related neuroendocrine tumor .</brief_summary>
	<brief_title>Disease-Specific Questionnaire Assessing Quality Life Patients With Gastrointestinal-Related Neuroendocrine Tumors</brief_title>
	<detailed_description>OBJECTIVES : Primary - Test scale structure , reliability , validity gastrointestinal neuroendocrine tumor module ( QLQ-G.I.NET21 ) patient gastrointestinal-related neuroendocrine tumor . Secondary - Determine quality life patient use QLQ-C30 QLQ-G.I.NET21 treatment . OUTLINE : This multicenter study . Patients stratify accord treatment ( somatostatin analogue therapy interferon therapy v radionuclide therapy chemotherapy v ablative therapy [ embolization radiofrequency ablation ] liver resection ) . Patients complete EORTC C30 questionnaire , QLQ-G.I.NET21 module , evaluate Karnofsky performance status pretreatment , 3 6 month treatment , 2 week later . Patients also complete clinical data sociodemographic data form debriefing questionnaire pretreatment ; follow-up form 3 month 6 month treatment ; test-retest form 2 week later . PROJECTED ACCRUAL : A total 408 patient accrue study .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Neuroendocrine Tumors</mesh_term>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<mesh_term>Malignant Carcinoid Syndrome</mesh_term>
	<mesh_term>Gastrointestinal Neoplasms</mesh_term>
	<mesh_term>Adenoma , Islet Cell</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm neuroendocrine tumor OR characteristic radiological finding neuroendocrine tumor raise hormone level plasma urine meeting follow criterion : Primary disease gut liver metastasis ( without hormone secretion ) Primary disease lung liver abdominal metastasis ( without hormone secretion ) Primary disease pancreas without metastasis ( without hormone secretion ) PATIENT CHARACTERISTICS : Any Karnofsky performance status allow Life expectancy â‰¥ 3 month Able understand questionnaire language Mentally fit complete questionnaire No psychological , familial , sociological , geographical condition would limit study compliance No concurrent malignancy except basal cell carcinoma skin PRIOR CONCURRENT THERAPY : More 2 month since prior somatostatin analogue interferon therapy ( somatostatin therapy stratum ) Concurrent somatostatin analogue and/or interferon therapy allow dose stable past month More 6 month since prior radionuclide therapy systemic chemotherapy ( radionuclide systemic chemotherapy stratum ) More 6 month since prior ablative therapy ( ablative therapy stratum ) No concurrent participation quality life study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2008</verification_date>
	<keyword>metastatic gastrointestinal carcinoid tumor</keyword>
	<keyword>recurrent gastrointestinal carcinoid tumor</keyword>
	<keyword>pulmonary carcinoid tumor</keyword>
	<keyword>gastrinoma</keyword>
	<keyword>insulinoma</keyword>
	<keyword>WDHA syndrome</keyword>
	<keyword>pancreatic polypeptide tumor</keyword>
	<keyword>somatostatinoma</keyword>
	<keyword>glucagonoma</keyword>
	<keyword>liver metastasis</keyword>
</DOC>